Dopaminergic abnormalities in amygdaloid nuclei in major depression: A postmortem study

Biological Psychiatry

Volumn 52, Issue 7, 2002, Pages 740-748

  Klimek, Violetta ^a,b   Schenck, Jane E ^a   Han, Hui ^a   Stockmeier, Craig A ^a   Ordway, Gregory A ^a  

^a UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MISSISSIPPI MEDICAL CENTER   (United States)

Author keywords

Amygdala; Autoradiography; Depression; Dopamine; Human

Indexed keywords

3BETA (4 IODOPHENYL) 2BETA TROPANECARBOXYLIC ACID METHYL ESTER; 8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; DOPAMINE TRANSPORTER; EPIDEPRIDE;

ADULT; AGED; AMYGDALOID NUCLEUS; ARTICLE; CADAVER; CLINICAL ARTICLE; CONTROLLED STUDY; DEPRESSION; DOPAMINERGIC SYSTEM; DRUG BINDING; FEMALE; HUMAN; HUMAN TISSUE; HYPOTHESIS; MALE; PRIORITY JOURNAL; REDUCTION;

ADULT; AGED; AGED, 80 AND OVER; AMYGDALA; AUTORADIOGRAPHY; DEPRESSIVE DISORDER, MAJOR; DOPAMINE; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; FEMALE; HUMANS; MALE; MEMBRANE GLYCOPROTEINS; MEMBRANE TRANSPORT PROTEINS; MIDDLE AGED; NERVE TISSUE PROTEINS; RADIOLIGAND ASSAY; RECEPTORS, DOPAMINE D1; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D3;

EID: 0036791096     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-3223(02)01383-5     Document Type: Article

References (67)

1. Abercrombie H.C., Schaefer S.M., Larson C.L., Oakes T.R., Lindgren K.A., Holden J.E., et al. Metabolic rate in the right amygdala predicts negative affect in depressed patients. Neuroreport. 9:1998;3301-3307.
2. Aggleton J.P. The contribution of the amygdala to normal and abnormal emotional states. Trends Neurosci. 16:1993;328-333.
3. American Psychiatric Association (1987): Diagnostic and Statistical Manual of Mental Disorders, Third Edition. Washington, DC.
4. Andreasen N.C., Endicott J., Spitzer R.L., Winokur G. The family history method using diagnostic criteria. Reliability and validity. Arch Gen Psychiatry. 34:1977;1229-1235.
5. Biegon A., Wolff M. Quantitative histochemistry of acetylcholinesterase in rat and human brain postmortem. J Neurosci Methods. 16:1986;39-45.
6. Charney D.S. Monoamine dysfunction and the pathophysiology and treatment of depression. J Clin Psychiatry. 59:(suppl 14):1998;11-14.
7. Chipkin R.E., McQuade R.D., Iorio L.C. D1 and D2 dopamine binding site up-regulation and apomorphine-induced stereotypy. Pharmacol Biochem Behav. 28:1987;477-482.
8. Ciliax B.J., Drash G.W., Staley J.K., Haber S., Mobley C.J., Miller G.W., et al. Immunocytochemical localization of the dopamine transporter in human brain. J Comp Neurol. 409:1999;38-56.
9. Ciliax B.J., Heilman C., Demchyshyn L.L., Pristupa Z.B., Ince E., Hersch S.M., et al. The dopamine transporter Immunochemical characterization and localization in brain . J Neurosci. 15:1995;1714-1723.
10. Coulter C.L., Happe H.K., Bergman D.A., Murrin L.C. Localization and quantification of the dopamine transporter Comparison of [3H]WIN 35,428 and [125I]RTI-55 . Brain Res. 690:1995;217-224.
11. Creese I., Snyder S.H. Nigrostriatal lesions enhance striatal 3H-apomorphine and 3H-spiroperidol binding. Eur J Pharmacol. 56:1979;277-281.
12. Demontis M.G., Fadda P., Devoto P., Martellotta M.C., Fratta W. Sleep deprivation increases dopamine D1 receptor antagonist [3H]SCH 23390 binding and dopamine-stimulated adenylate cyclase in the rat limbic system. Neurosci Lett. 117:1990;224-227.
13. D'haenen H.A., Bossuyt A. Dopamine D2 receptors in depression measured with single photon emission computed tomography. Biol Psychiatry. 35:1994;128-132.
14. Drevets W.C. Neuroimaging studies in mood disorders. Biol Psychiatry. 48:2000;801-812.
15. Drevets W.C., Raichle M.E. Neuroanatomical circuits in depression Implications for treatment mechanisms . Psychopharmacol Bull. 28:1992;261-274.
16. Drevets W.C., Videen T.O., Price J.L., Preskorn S.H., Carmichael S.T., Raichle M.E. A functional anatomical study of unipolar depression. J Neurosci. 12:1992;3628-3641.
17. Ebert D., Feistel H., Loew T., Pirner A. Dopamine and depression-striatal dopamine D2 receptor SPECT before and after antidepressant therapy. Psychopharmacology (Berl). 126:1996;91-94.
18. Edwards R.H. Neural degeneration and the transport of neurotransmitters. Ann Neurol. 34:1993;638-645.
19. Endicott J., Spitzer R.L. A diagnostic interview The schedule for affective disorders and schizophrenia . Arch Gen Psychiatry. 35:1978;837-844.
20. Fallon J.H., Ciofi P. Distribution of monoamines within the amygdala. Aggleton J.P., The Amygdala: Neurobiological Aspects of Emotion, Memory, and Mental Dysfunction. 1992;97-114 Wiley-Liss, New York.
21. Gordon I., Weizman R., Rehavi M. Modulatory effect of agents active in the presynaptic dopaminergic system on the striatal dopamine transporter. Eur J Pharmacol. 298:1996;27-30.
22. Gurevich E.V., Joyce J.N. Distribution of dopamine D3 receptor expressing neurons in the human forebrain Comparison with D2 receptor expressing neurons . Neuropsychopharmacology. 20:1999;60-80.
23. Halaris A.E., Belendiuk K.T., Freedman D.X. Antidepressant drugs affect dopamine uptake. Biochem Pharmacol. 24:1975;1896-1897.
24. Joyce J.N. Dopamine D(3) receptor as a therapeutic target for antipsychotic and antiparkinsonian drugs. Pharmacol Ther. 90:2001;231-259.
25. 125I] epidepride binding to dopamine D2 receptors in basal ganglia and cortex of human brain. J Pharmacol Exp Ther. 257:1991;1253-1263.
26. Joyce J.N., Murray A. Distribution of D1- and D2-like dopamine receptors in human brain. Niznik H.B., Dopamine Receptors and Transporters; Pharmacology, Structure and Function. 1994;345-382 Marcel Dekker, New York.
27. Klimek V., Maj J. Repeated administration of antidepressants enhances agonist affinity for mesolimbic D2-receptors. J Pharm Pharmacol. 41:1989;555-558.
28. Klimek V., Stockmeier C.A., Overholser J.C., Meltzer H.Y., Kalka S., Dilley G., Ordway G.A. Reduced levels of norepinephrine transporters in the locus coeruleus in major depression. J Neurosci. 17:1997;8451-8458.
29. Kuhar M.J. Recent biochemical studies of the dopamine transporter A CNS drug target . Life Sci. 62:1998;1573-1575.
30. Lambert G., Johansson M., Agren H., Friberg P. Reduced brain norepinephrine and dopamine release in treatment-refractory depressive illness Evidence in support of the catecholamine hypothesis of mood disorders . Arch Gen Psychiatry. 57:2000;787-793.
31. Little K.Y., Carroll F.I., Cassin B.J. Characterization and localization of [125I]RTI-121 binding sites in human striatum and medial temporal lobe. J Pharmacol Exp Ther. 274:1995;1473-1483.
32. Little K.Y., Kirkman J.A., Carroll F.I., Clark T.B., Duncan G.E. Cocaine use increases [3H]WIN 35428 binding sites in human striatum. Brain Res. 628:1993;17-25.
33. Lorang D., Amara S.G., Simerly R.B. Cell-type-specific expression of catecholamine transporters in the rat brain. J Neurosci. 14:1994;4903-4914.
34. Maj J., Rogóz Z., Skuza G., Sowinska H. Repeated treatment with antidepressant drugs potentiates the locomotor response to (+)-amphetamine. J Pharm Pharmacol. 36:1984;127-130.
35. Maj J., Skuza G., Sowinska H. Repeated treatment with antidepressant drugs increases the behavioural response to apomorphine. J Neural Transm. 60:1984;273-282.
36. Maj J., Wedzony K., Klimek V. Desipramine given repeatedly enhances behavioural effects of dopamine and D-amphetamine injected into the nucleus accumbens. Eur J Pharmacol. 140:1987;179-185.
37. Major L.F., Murphy D.L., Lipper S., Gordon E. Effects of clorgyline and pargyline on deaminated metabolites of norepinephrine, dopamine and serotonin in human cerebrospinal fluid. J Neurochem. 32:1979;229-231.
38. 1 binding density following mesotelencephalic 6-hydroxydopamine injections An autoradiographic analysis . Brain Res. 493:1989;247-257.
39. Mayberg H.S. Limbic-cortical dysregulation A proposed model of depression . J Neuropsychiatry Clin Neurosci. 9:1997;471-481.
40. 3H]SCH 23390 binding. Brain Res. 483:1989;117-122.
41. Murray A.M., Ryoo H.L., Gurevich E., Joyce J.N. Localization of dopamine D3 receptors to mesolimbic and D2 receptors to mesostriatal regions of human forebrain. Proc Natl Acad Sci USA. 91:1994;11271-11275.
42. 125I]epidepride, a high-affinity substituted benzamide ligand. J Pharmacol Exp Ther. 252:1990;1108-1116.
43. Nirenberg M.J., Chan J., Pohorille A., Vaughan R.A., Uhl G.R., Kuhar M.J., Pickel V.M. The dopamine transporter Comparative ultrastructure of dopaminergic axons in limbic and motor compartments of the nucleus accumbens . J Neurosci. 17:1997;6899-6907.
44. Nirenberg M.J., Vaughan R.A., Uhl G.R., Kuhar M.J., Pickel V.M. The dopamine transporter is localized to dendritic and axonal plasma membranes of nigrostriatal dopaminergic neurons. J Neurosci. 16:1996;436-447.
45. Norman A.B., Battaglia G., Creese I. Differential recovery rates of rat D2 dopamine receptors as a function of aging and chronic reserpine treatment following irreversible modification A key to receptor regulatory mechanisms . J Neurosci. 7:1987;1484-1491.
46. Ordway G.A., Stockmeier C.A., Cason G.W., Klimek V. Pharmacology and distribution of norepinephrine transporters in the human locus coeruleus and raphe nuclei. J Neurosci. 17:1997;1710-1719.
47. Papp M., Klimek V., Willner P. Parallel changes in dopamine D2 receptor binding in limbic forebrain associated with chronic mild stress-induced anhedonia and its reversal by imipramine. Psychopharmacology (Berl). 115:1994;441-446.
48. Randrup A., Munkvad I., Fog R., Gerlach J., Molander L., Kielberg B., Scheel-Kruger J. Mania, depression and brain dopamine. Essman W.B., Valzelli L., Current Developments in Psychopharmacology. 1975;206-248 Spectrum, New York.
49. Revay R., Vaughan R., Grant S., Kuhar M.J. Dopamine transporter immunohistochemistry in median eminence, amygdala, and other areas of the rat brain. Synaps. 22:1996;93-99.
50. Robbins L., Cottler L., Keating S. NIMH Diagnostic Interview Schedule. Version III - Revised (DIS-III-R). 1989;Washington University Department of Psychiatry, St. Louis, MO.
51. Roseboom P.H., Gnegy M.E. Acute in vivo amphetamine produces a homologous desensitization of dopamine receptor-coupled adenylate cyclase activities and decreases agonist binding to the D1 site. Mol Pharmacol. 35:1989;139-147.
52. Ryoo H.L., Pierrotti D., Joyce J.N. Dopamine D3 receptor is decreased and D2 receptor is elevated in the striatum of Parkinson's disease. Mov Disord. 13:1998;788-797.
53. Shah P.J., Ogilvie A.D., Goodwin G.M., Ebmeier K.P. Clinical and psychometric correlates of dopamine D2 binding in depression. Psychol Med. 27:1997;1247-1256.
54. Shapiro L.A., Offord S.J., Ordway G.A. The effect of chronic treatment with a novel aryl-piperazine antipsychotic on monoamine receptors in rat brain. Brain Res. 677:1995;250-256.
55. Sheline Y.I., Gado M.H., Price J.L. Amygdala core nuclei volumes are decreased in recurrent major depression. Neuroreport. 9:1998;2023-2028.
56. Shin L.M., Kosslyn S.M., McNally R.J., Alpert N.M., Thompson W.L., Rauch S.L. Visual imagery and perception in posttraumatic stress disorder. A positron emission tomographic investigation. Arch Gen Psychiatry. 54:1997;233-241.
57. Sims K.S., Williams R.S. The human amygdaloid complex A cytologic and histochemical atlas using Nissl, myelin, acetylcholinesterase and nicotinamide adenine dinucleotide phosphate diaphorase staining . Neuroscience. 36:1990;449-472.
58. Suhara T., Nakayama K., Inoue O., Fukuda H., Shimizu M., Mori A., Tateno Y. D1 dopamine receptor binding in mood disorders measured by positron emission tomography. Psychopharmacology (Berl). 106:1992;14-18.
59. Swerdlow N.R., Koob G.F. Dopamine, schizophrenia, mania, and depression Toward a unified hypothesis of cortico-striato-pallido-thalamic function . Behav Brain Sci. 10:1987;197-245.
60. Traub M., Reches A., Wagner H.R., Fahn S. Reserpine-induced up-regulation of dopamine D2 receptors in the rat striatum is enhanced by denervation but not by chronic receptor blockade. Neurosci Lett. 70:1986;245-249.
61. Vijayashankar N., Lele J.V., Daginawala H.F. Effect of reserpine on the monoamine oxidase (MAO) activity in rat liver and brain. Biochem Pharmacol. 27:1978;1985-1986.
62. Weiss J.M., Goodman P.A., Losito B.G., Corrigan S., Charry J.M., Bailey W.H. Behavioral depression produced by an uncontrollable stressor Relationship to norepinephrine, dopamine, and serotonin levels in various regions of rat brain . Brain Res Rev. 3:1981;167-205.
63. Willner P. Dopamine and depression A review of recent evidence. II. Theoretical approaches . Brain Res. 287:1983;225-236.
64. Willner P. Dopamine and depression A review of recent evidence. III. The effects of antidepressant treatments . Brain Res. 287:1983;237-246.
65. Willner P. Dopaminergic mechanisms in depression and mania. Bloom F.E., Kupfer D.J., Psychopharmacology: The Fourth Generation of Progress. 1995;921-931 Raven Press, New York.
66. Wong D.F., Ricaurte G., Grunder G., Rothman R., Naidu S., Singer H., Harris J., et al. Dopamine transporter changes in neuropsychiatric disorders. Adv Pharmacol. 42:1998;219-223.
67. Zhang L., Elmer L.W., Little K.Y. Expression and regulation of the human dopamine transporter in a neuronal cell line. Brain Res Mol Brain Res. 59:1998;66-73.